{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:46Z","timestamp":1786118446254,"version":"build-2736575974"},"reference-count":53,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,7,13]]},"DOI":"10.2967\/jnumed.126.272210","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:55:20Z","timestamp":1786031720000},"page":"jnumed.126.272210","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms"],"prefix":"10.2967","author":[{"given":"Wallace Klein","family":"Schwengber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Pinteric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Kusne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026080608551251000_jnumed.126.272210v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026080608551251000_jnumed.126.272210v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026080608551251000_jnumed.126.272210v1.3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol."},{"key":"2026080608551251000_jnumed.126.272210v1.4","doi-asserted-by":"crossref","first-page":"S1742","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol."},{"key":"2026080608551251000_jnumed.126.272210v1.5","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2026080608551251000_jnumed.126.272210v1.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.189712"},{"key":"2026080608551251000_jnumed.126.272210v1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2026080608551251000_jnumed.126.272210v1.8","doi-asserted-by":"crossref","first-page":"e250025","DOI":"10.1530\/ERC-25-0025","article-title":"Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?","volume":"32","author":"Kusne","year":"2025","journal-title":"Endocr Relat Cancer."},{"key":"2026080608551251000_jnumed.126.272210v1.9","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.34191","article-title":"Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer."},{"key":"2026080608551251000_jnumed.126.272210v1.10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/ERC-21-0082","article-title":"Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET","volume":"28","author":"Kesavan","year":"2021","journal-title":"Endocr Relat Cancer."},{"key":"2026080608551251000_jnumed.126.272210v1.11","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0543"},{"key":"2026080608551251000_jnumed.126.272210v1.12","doi-asserted-by":"crossref","first-page":"107434","DOI":"10.1016\/j.leukres.2023.107434","article-title":"Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to lutetium-177-Dotatate","volume":"136","author":"Pritzl","year":"2024","journal-title":"Leuk Res."},{"key":"2026080608551251000_jnumed.126.272210v1.13","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/1078-0432.CCR-25-1884","article-title":"A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate\/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumors","volume":"32","author":"Becx","year":"2026","journal-title":"Clin Cancer Res."},{"key":"2026080608551251000_jnumed.126.272210v1.14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-024-01077-7","article-title":"Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy","volume":"14","author":"Persson","year":"2024","journal-title":"EJNMMI Res."},{"key":"2026080608551251000_jnumed.126.272210v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026080608551251000_jnumed.126.272210v1.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268640"},{"key":"2026080608551251000_jnumed.126.272210v1.17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286808"},{"key":"2026080608551251000_jnumed.126.272210v1.18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res."},{"key":"2026080608551251000_jnumed.126.272210v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268902"},{"key":"2026080608551251000_jnumed.126.272210v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617"},{"key":"2026080608551251000_jnumed.126.272210v1.21","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2352-3026(23)00340-X","article-title":"Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study","volume":"11","author":"Cargo","year":"2024","journal-title":"Lancet Haematol."},{"key":"2026080608551251000_jnumed.126.272210v1.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-763425"},{"key":"2026080608551251000_jnumed.126.272210v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2017.07.010"},{"key":"2026080608551251000_jnumed.126.272210v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00710-0"},{"key":"2026080608551251000_jnumed.126.272210v1.25","doi-asserted-by":"crossref","first-page":"e2100309","DOI":"10.1200\/PO.21.00309","article-title":"Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy","volume":"6","author":"Singh","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026080608551251000_jnumed.126.272210v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.10.004"},{"key":"2026080608551251000_jnumed.126.272210v1.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006510"},{"key":"2026080608551251000_jnumed.126.272210v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/nature13968"},{"key":"2026080608551251000_jnumed.126.272210v1.29","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.04.012"},{"key":"2026080608551251000_jnumed.126.272210v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.60"},{"key":"2026080608551251000_jnumed.126.272210v1.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0890"},{"key":"2026080608551251000_jnumed.126.272210v1.32","doi-asserted-by":"crossref","first-page":"e2400143","DOI":"10.1200\/PO.24.00143","article-title":"Clonal hematopoiesis in patients with neuroendocrine tumor treated with lutetium-177 and the risk of thrombocytopenia: a prospective study","volume":"8","author":"Kusne","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2026080608551251000_jnumed.126.272210v1.33","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.2023020331","article-title":"PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy","volume":"142","author":"Miller","year":"2023","journal-title":"Blood."},{"key":"2026080608551251000_jnumed.126.272210v1.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265484"},{"key":"2026080608551251000_jnumed.126.272210v1.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2026080608551251000_jnumed.126.272210v1.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1072-6"},{"key":"2026080608551251000_jnumed.126.272210v1.37","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1016\/S2352-3026(25)00137-1","article-title":"Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time","volume":"12","author":"Kirschner","year":"2025","journal-title":"Lancet Haematol."},{"key":"2026080608551251000_jnumed.126.272210v1.38","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1014","article-title":"Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors [abstract]","volume":"33(suppl 7)","author":"El Ferkh","year":"2022","journal-title":"Ann Oncol."},{"key":"2026080608551251000_jnumed.126.272210v1.39","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood-2024-204958","article-title":"Emergence of DNA damage repair clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors [abstract]","volume":"144","author":"Loyaux","year":"2024","journal-title":"Blood."},{"key":"2026080608551251000_jnumed.126.272210v1.40","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1078-0432.CCR-25-4001","article-title":"Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer","volume":"32","author":"Munzur","year":"2026","journal-title":"Clin Cancer Res."},{"key":"2026080608551251000_jnumed.126.272210v1.41","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.7150\/thno.113354","article-title":"Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells","volume":"15","author":"Nguyen","year":"2025","journal-title":"Theranostics."},{"key":"2026080608551251000_jnumed.126.272210v1.42","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1549-3"},{"key":"2026080608551251000_jnumed.126.272210v1.43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270979"},{"key":"2026080608551251000_jnumed.126.272210v1.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2026080608551251000_jnumed.126.272210v1.45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026080608551251000_jnumed.126.272210v1.46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40658-024-00636-0","article-title":"Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT\/CT","volume":"11","author":"Grob","year":"2024","journal-title":"EJNMMI Phys."},{"key":"2026080608551251000_jnumed.126.272210v1.47","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00259-025-07541-3","article-title":"Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET\/CT imaging","volume":"53","author":"Borges","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026080608551251000_jnumed.126.272210v1.48","first-page":"P318","article-title":"Correlation between the total osseus tumor volume and the development of hematologic toxicities in patients with metastatic castrate-resistant prostate cancer receiving 177Lu-PMSA-617 [abstract]","volume":"64(suppl 1)","author":"Abdelrahman","year":"2023","journal-title":"J Nucl Med."},{"key":"2026080608551251000_jnumed.126.272210v1.49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-019-0548-z","article-title":"3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT\/CT","volume":"9","author":"Gosewisch","year":"2019","journal-title":"EJNMMI Res."},{"key":"2026080608551251000_jnumed.126.272210v1.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270916"},{"key":"2026080608551251000_jnumed.126.272210v1.51","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266843"},{"key":"2026080608551251000_jnumed.126.272210v1.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05727-7"},{"key":"2026080608551251000_jnumed.126.272210v1.53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-026-02526-w","article-title":"CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis","volume":"58","author":"Chan","year":"2026","journal-title":"Nat Genet."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:55:23Z","timestamp":1786031723000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":53,"alternative-id":["10.2967\/jnumed.126.272210"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272210","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}